BRPI0807483A2 - Compostos e composições como inibidores de protease de ativação de canal - Google Patents

Compostos e composições como inibidores de protease de ativação de canal

Info

Publication number
BRPI0807483A2
BRPI0807483A2 BRPI0807483-6A2A BRPI0807483A BRPI0807483A2 BR PI0807483 A2 BRPI0807483 A2 BR PI0807483A2 BR PI0807483 A BRPI0807483 A BR PI0807483A BR PI0807483 A2 BRPI0807483 A2 BR PI0807483A2
Authority
BR
Brazil
Prior art keywords
compositions
compounds
protease inhibitors
channel activate
activate protease
Prior art date
Application number
BRPI0807483-6A2A
Other languages
English (en)
Inventor
David C Tully
Arnab K Chatterjee
Zhiwei Wang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0807483A2 publication Critical patent/BRPI0807483A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0807483-6A2A 2007-02-09 2008-01-07 Compostos e composições como inibidores de protease de ativação de canal BRPI0807483A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88901807P 2007-02-09 2007-02-09
PCT/US2008/050403 WO2008097676A1 (en) 2007-02-09 2008-01-07 Compounds and compositions as channel activating protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0807483A2 true BRPI0807483A2 (pt) 2014-05-13

Family

ID=39323929

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807483-6A2A BRPI0807483A2 (pt) 2007-02-09 2008-01-07 Compostos e composições como inibidores de protease de ativação de canal

Country Status (11)

Country Link
US (1) US8293915B2 (pt)
EP (1) EP2117537A1 (pt)
JP (1) JP2010518099A (pt)
KR (1) KR20090108131A (pt)
CN (1) CN101600428A (pt)
AU (1) AU2008214217B2 (pt)
BR (1) BRPI0807483A2 (pt)
CA (1) CA2677487A1 (pt)
EA (1) EA016327B1 (pt)
MX (1) MX2009008518A (pt)
WO (1) WO2008097676A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027143A2 (en) 2006-05-23 2009-02-25 Irm Llc Compounds and compositions as channel activating protease inhibitors
CA2677487A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
SG175711A1 (en) 2009-05-18 2011-12-29 Orion Corp Protease inhibitors
MY162786A (en) * 2011-07-26 2017-07-14 Sanofi Sa Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals
MX2014006211A (es) * 2011-11-25 2014-08-08 Hoffmann La Roche Nuevos derivados de pirrolidina como inhibidores de catepsina.
US10399940B2 (en) * 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7692353B2 (ja) 2018-10-02 2025-06-13 ディスク・メディスン,インコーポレイテッド マトリプターゼ2阻害剤及びその使用
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣3多肽之持續遞送
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
HUE064089T2 (hu) 2020-04-16 2024-02-28 Mereo Biopharma 4 Ltd Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809316D0 (en) 1987-05-11 1988-05-25 Ici America Inc Heterocyclic ketones
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
KR100347285B1 (ko) * 1994-06-02 2003-01-15 아벤티스 파마슈티칼스 인크. 신규의엘라스타제저해제
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6211154B1 (en) * 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
TW523513B (en) 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
CA2253835A1 (en) 1996-06-18 1997-12-24 Kent Alan Berryman Process for the preparation of chiral keto-heterocycles of basic amino acids
IL121474A0 (en) 1996-08-23 1998-02-08 Akzo Nobel Nv Thrombin inhibitors
NZ335276A (en) * 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
TR199901681T2 (xx) 1996-12-06 2000-03-21 Cortech, Inc. Serin proteas inhibit�rleri.
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
TR199902692T2 (xx) 1997-05-02 2000-07-21 Akzo Nobel N.V. Serin proteaz inhibit�rleri.
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
EP1114822A3 (en) 1998-06-03 2002-11-13 Cortech Inc. Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
BR0007778A (pt) 1999-01-27 2002-06-04 Ortho Mcneil Pharm Inc Peptidila cetonas heterocìclicas úteis como inibidores de triptase
JP2000256396A (ja) * 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
GB9923710D0 (en) 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
AU2055301A (en) * 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
JP2002138048A (ja) * 2000-08-25 2002-05-14 Dainippon Pharmaceut Co Ltd 複素環式化合物からなる医薬
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
KR100926244B1 (ko) 2001-07-11 2009-11-12 버텍스 파마슈티칼스 인코포레이티드 브릿지된 바이사이클릭 세린 프로테아제 억제제
EP1480999A2 (en) 2002-02-08 2004-12-01 Idun Pharmaceuticals (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7205384B2 (en) 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NZ546663A (en) 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
KR20060118532A (ko) 2003-12-11 2006-11-23 쉐링 코포레이션 C형 간염 바이러스 ns3/ns4a 세린 프로테아제의억제제
US20050222383A1 (en) 2004-02-05 2005-10-06 Irm Llc Prostasin substrates and inhibitors
RU2006134005A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
EP1727811B1 (en) 2004-03-24 2014-11-12 Shire Orphan Therapies GmbH New compounds for the inhibition of angiogenesis and use of thereof
CN1984922A (zh) 2004-05-20 2007-06-20 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
WO2006006644A1 (ja) 2004-07-14 2006-01-19 Kyowa Hakko Kogyo Co., Ltd. 複素環式化合物
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
EP2019837B1 (en) * 2006-05-23 2011-03-23 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2027143A2 (en) 2006-05-23 2009-02-25 Irm Llc Compounds and compositions as channel activating protease inhibitors
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
CA2677487A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
CA2677485A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors

Also Published As

Publication number Publication date
EP2117537A1 (en) 2009-11-18
JP2010518099A (ja) 2010-05-27
MX2009008518A (es) 2009-08-20
KR20090108131A (ko) 2009-10-14
EA016327B1 (ru) 2012-04-30
WO2008097676A1 (en) 2008-08-14
CA2677487A1 (en) 2008-08-14
US20100056756A1 (en) 2010-03-04
AU2008214217A1 (en) 2008-08-14
EA200901083A1 (ru) 2010-02-26
AU2008214217B2 (en) 2011-10-13
CN101600428A (zh) 2009-12-09
US8293915B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
BRPI0806970A2 (pt) Compostos e composições como inibidores de protease de ativação de canal
BRPI0816786A2 (pt) Canal
BRPI0922084A2 (pt) Composições e métodos compreendendo variantes de serina protease
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
LTPA2017010I1 (lt) Proteazomos inhibitoriai
ATE461177T1 (de) Ionenkanal-hemmer
BRPI0719499A2 (pt) Composições de poliolefina
EP2046887A4 (en) Light-Crosslinkable Polyolefin Compositions
BRPI0808192A2 (pt) composto e composições como moduladores de atividades de gpr119
BRPI0914652A2 (pt) compostos e composições como inibidores de quinase
BRPI0912668A2 (pt) composto e composições como inibidores de quinase
BRPI0810634A2 (pt) Composições fungicidas
PL2104535T3 (pl) Związki i kompozycje jako inhibitory proteazy aktywujące kanały
HUE059171T2 (hu) Kompozíciók
EP2218175A4 (en) Switching amplifiers
LT3575288T (lt) Chinazolinai kaip kalio jonų kanalų inhibitoriai
EP2381760A4 (en) CORN PROTEIN COMPOSITION
BRPI0816494A2 (pt) Composição vedante melhorada
PL2019837T3 (pl) Związki i kompozycje jako inhibitory proteazy aktywującej kanały
BRPI0810557A2 (pt) composição
BRPI0910979A2 (pt) compostos e composições como inibidores de quinase
BRPI0914545A2 (pt) compostos e composições como inibidores de quinase
DK2214640T3 (da) Intranasale sammensætninger
BRPI0718141A2 (pt) Composições de frangrâncias
BRPI0910691A2 (pt) compostos e composições como inibidores de itpkb

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.